BioAdvance News KaloCyte Portfolio News

KaloCyte Closes Investment from New York Blood Center

By WebmasterJuly 20, 2022November 1st, 2024No Comments

KaloCyte Closes Investment from New York Blood Center

This funding will be used to support KaloCyte as it scales up in advance of human trials

Previous PostWellsheet Recognized as a Sample Vendor in Smart EHR UI in a Gartner Report
Next PostEliksa Therapeutics launched with University of Utah’s commercial and clinical-stage regenerative medicine technology